Combating Resistance in Antibiotic Drug Discovery and Development
The epidemiology of increasing resistance problem continues to garner much attention. A bacteria capable of opposing the inhibitory (bacteriostatic) or killing (bacteriocidal) effects of antibiotics has unfortunately become an increasingly common occurrence and presents a serious threat to successful treatment of bacterial infections. In this interview Dr. Mark Brian Anderson, Chief Scientific Officer at NovaBay Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about the growing market...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.